Search results for "HERA"

showing 10 items of 14928 documents

FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines

2016

Intranodal immunization with antigen-encoding naked mRNA has proven to be an efficacious and safe approach to induce antitumor immunity. Thanks to its unique characteristics, mRNA can act not only as a source for antigen but also as an adjuvant for activation of the immune system. The search for additional adjuvants that can be combined with mRNA to further improve the potency of the immunization revealed Fms-like tyrosine kinase 3 (FLT3) ligand as a potent candidate. Systemic administration of the dendritic cell-activating FLT3 ligand prior to or along with mRNA immunization-enhanced priming and expansion of antigen-specific CD8(+) T cells in lymphoid organs, T-cell homing into melanoma tu…

0301 basic medicineChemistrymedicine.medical_treatmentPriming (immunology)chemical and pharmacologic phenomenaImmunotherapyDendritic cellbiochemical phenomena metabolism and nutrition03 medical and health sciences030104 developmental biologyImmune systemAntigenSystemic administrationmedicineCancer researchbacteriaAdjuvantCD8
researchProduct

Bevacizumab diminishes inflammation in an acute endotoxin-induced uveitis model

2017

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.frontiersin.org/articles/10.3389/fphar.2018.00649/full Introduction: Uveitis is an eye disease characterized by inflammation of the uvea and an early and exhaustive diagnosis is essential for its treatment. The aim of our study is to assess the potential toxicity and anti-inflammatory efficacy of Bevacizumab in an experimental uveitis model by subcutaneously injecting lipopolysaccharide into Lewis rats and to clarify its mechanism. Material and Methods: Blood–aqueous barrier integrity was assessed 24 h after endotoxin-induced uveitis (EIU) by analyzing two parameters: cell count and protein…

0301 basic medicineChemokineLipopolysaccharidegenetic structuresmedicine.medical_treatmentÚvea - Efectos de los medicamentos.chemokinesPharmacologymedicine.disease_causeendotoxin-induced uveitischemistry.chemical_compound0302 clinical medicineMedicineoxidative stressPharmacology (medical)Bevacizumab - Efectos fisiológicos.Bevacizumab - Efectos secundarios.Uvea - Effect of drugs on.Original ResearchEstrés oxidativo.biologyOxidative stress.medicine.anatomical_structureCytokineToxicityOjos - Enfermedades - Tratamiento.medicine.symptomUveitisPharmacology.InflammationFarmacología.bevacizumabBevacizumab - Physiological effect.Bevacizumab - Side effects.03 medical and health sciencesUveitis - Treatment.Eyes - Diseases - Treatment.Pharmacologybusiness.industrylcsh:RM1-950Uveítis - Tratamiento.Uveamedicine.diseaseeye diseasescytokines030104 developmental biologylcsh:Therapeutics. Pharmacologychemistryinflammation030221 ophthalmology & optometrybiology.proteinsense organsbusinessOxidative stress
researchProduct

IL-10-Modulated Human Dendritic Cells for Clinical Use: Identification of a Stable and Migratory Subset with Improved Tolerogenic Activity.

2015

Abstract Dendritic cells (DCs) are key regulators of protective immune responses and tolerance to (self-)Ags. Therefore, the scientific rationale for the use of tolerogenic DC therapy in the fields of allergies, autoimmunity, and transplantation medicine is strong. In this study, we analyzed the tolerogenic capacity of IL-10–modulated DC (IL-10DC) subpopulations to identify a DC subset that combines potent immunosuppressive activities with valuable immune properties for clinical implementation. IL-10DCs consist of two phenotypically distinct subpopulations: CD83highCCR7+ IL-10DCs and CD83lowCCR7− IL-10DCs. Suppressor assays with activated effector T cells revealed that CD4+ regulatory T cel…

0301 basic medicineChemokineReceptors CCR7medicine.medical_treatmentImmunologyImmunoglobulinsBiologymedicine.disease_causeLymphocyte ActivationT-Lymphocytes RegulatoryAutoimmunity03 medical and health sciencesImmune systemAntigens CDCell MovementmedicineImmune ToleranceImmunology and AllergyHumansIL-2 receptorCells CulturedInflammationMembrane GlycoproteinsChemokine CCL21Interleukin-2 Receptor alpha SubunitCell DifferentiationDendritic CellsInterleukin-10Interleukin 10Tolerance induction030104 developmental biologyCytokineImmunologybiology.proteinImmunotherapyCCL21Journal of immunology (Baltimore, Md. : 1950)
researchProduct

Natural Compounds: Molecular Weapons against Leukemia’s

2017

Nowadays cancer is one of the main reasons of death all over the world and it is estimated that deaths caused by cancer will grow dramatically in the next decades. Even if chemotherapy is the election therapy for solid tumors, as well as leukemias and lymphomas, cancer treatments are in continuous evolution trying to solve the problem of resistance mainly due to low accumulation of the drug in tumor cells (MDR). Natural compounds represent a valid alternative to treat several disease and recently the scientific community focus on these natural compounds and plant metabolites with therapeutic activities and low toxicities compared with synthetic ones. A combination therapy, that join convent…

0301 basic medicineChemotherapyCombination therapybusiness.industrymedicine.medical_treatmentChronic lymphocytic leukemiaCancerDiseasemedicine.diseaseBioinformaticsNatural (archaeology)03 medical and health sciencesLeukemia030104 developmental biology0302 clinical medicineSettore BIO/13 - Biologia Applicata030220 oncology & carcinogenesismedicineHairy cell leukemiaNatural Compounds leukemiabusiness
researchProduct

2020

Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies such as chemotherapy, radiation, or vaccines, which can stimulate the immune system and recruit antitumor T cells into the tumor bed, may be a relevant strategy to increase the proportion of responding patients. Such an approach still raises the following questions: What are the immunological features modulated by immunogenic therapies that can be critical to ensure not only immediate but also l…

0301 basic medicineChemotherapyTumor microenvironmentbusiness.industrymedicine.medical_treatmentImmune checkpoint inhibitorsCancerGeneral Medicinemedicine.disease3. Good healthRadiation therapy03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemCancer immunotherapy030220 oncology & carcinogenesisCancer researchmedicinePermissivebusinessCells
researchProduct

2018

Background: Chemotherapy is currently evaluated in order to enhance the efficacy of immune checkpoint blockade (ICB) therapy in colorectal cancer. However, the mechanisms by which these drugs could...

0301 basic medicineChemotherapybiologyColorectal cancerMechanism (biology)business.industrymedicine.medical_treatmentImmunologyImmunotherapymedicine.diseaseImmune checkpoint3. Good healthBlockade03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisPD-L1medicineCancer researchbiology.proteinImmunology and AllergyCytotoxic T cellbusinessOncoImmunology
researchProduct

Evaluation of Long-Time Decoction-Detoxicated Hei-Shun-Pian (Processed Aconitum carmichaeli Debeaux Lateral Root With Peel) for Its Acute Toxicity an…

2020

Background As a degenerative joint disease with severe cartilage destruction and pain, osteoarthritis (OA) has no satisfactory therapy to date. In traditional Chinese medicine (TCM), Aconitum carmichaeli Debeaux derived Hei-shun-pian (Hsp) has been developed for joint pain treatment. However, it causes adverse events in OA patients. Long-time decoction has been traditionally applied to reduce the aconite toxicity of Hsp and other aconite herbs, but its detoxifying effect is uncertain. Methods Hsp was extracted with dilute decoction times (30, 60, and 120 min) and evaluated by toxicological, chemical, pharmacological assays. Acute toxicity assay and chemical analysis were employed to determi…

0301 basic medicineChondrocyte hypertrophyDecoctionOsteoarthritisPharmacology03 medical and health scienceschemistry.chemical_compoundtraditional Chinese medicine0302 clinical medicineTherapeutic indexAconitum carmichaeliMedicineAconitinePharmacology (medical)Viability assayOriginal ResearchPharmacologybusiness.industrylcsh:RM1-950monosodium iodoacetateanalgesiapain behaviourmedicine.diseaseAcute toxicityosteoarthritis030104 developmental biologylcsh:Therapeutics. Pharmacologychemistry030220 oncology & carcinogenesisToxicitybusinessFrontiers in Pharmacology
researchProduct

A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles

2015

Current approaches for the treatment of chronic lymphocytic leukemia (CLL) have greatly improved the prognosis for survival, but some patients remain refractive to these therapeutic regimens. Hence, in addition to reducing the long-term sideeffects of therapeutics for all leukemia patients, there is an urgent need for novel therapeutic strategies for difficult-to-treat leukemia cases. Due to the cytotoxicity of drugs, the major challenge currently is to deliver the therapeutic agents to neoplastic cells while preserving the viability of non-malignant cells. In this study, we propose a therapeutic approach in which high doses of hydroxychloroquine and chlorambucil were loaded into biodegrada…

0301 basic medicineChronic lymphocytic leukemiaxenograft modelchronic lymphocytic leukemia; immune targeted nanoparticles; treatment; xenograft model; Electrical and Electronic Engineering; Materials Science (all)Nanotechnology03 medical and health sciencesTherapeutic approach0302 clinical medicinehemic and lymphatic diseasesmedicineGeneral Materials ScienceElectrical and Electronic EngineeringCytotoxicityCD20immune targeted nanoparticletreatmentChlorambucilbiologybusiness.industryTherapeutic effectHydroxychloroquineCondensed Matter Physicsmedicine.diseaseAtomic and Molecular Physics and OpticsLeukemia030104 developmental biology030220 oncology & carcinogenesisimmune targeted nanoparticlesCancer researchbiology.proteinchronic lymphocytic leukemiaMaterials Science (all)businessmedicine.drugNano Research
researchProduct

<p>Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data</p>

2020

Background/Aim Up to 30% of all patients will present with an advanced or a metastatic stage (mUCC) at the moment of the initial diagnosis of urothelial cell carcinoma of the bladder (UCC). We investigated the numbers, the efficacy and toxicity of different chemotherapies for mUCC in daily practice and "real-life" conditions and evaluated them substance-specifically. Patients and Methods All patients with a mUCC, who were treated between January 1, 2006 and October 31, 2016 at the Department of Urology and Pediatric Urology at University Hospital Marburg (Germany), were retrospectively analyzed. We set the focus on demographic and tumor-specific data as well as on effectiveness, therapy seq…

0301 basic medicineCisplatinOncologyChemotherapymedicine.medical_specialtyBladder cancerMetastatic Urothelial Carcinomabusiness.industrymedicine.medical_treatmentmedicine.diseaseGemcitabinePediatric urology03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyUrothelial cell carcinoma030220 oncology & carcinogenesisInternal medicinemedicineStage (cooking)businessmedicine.drugCancer Management and Research
researchProduct

Human Leukocyte Antigens Class II Alleles Affecting the Response to 5–7 Year Antiretroviral Therapy in A Latvian Cohort

2019

Abstract Antiretroviral therapy (ART) aims at suppressing viral replication and strengthening immune system in patients with HIV-1. Human Leukocyte Antigens (HLA) are among factors responsible for effectiveness of ART. The aim of this study was to determine the effect of HLA Class II alleles on the response to long-time ART, assessed by a change in CD4+ T-cell count in relation to viral load. The sample included 69 patients (17 females and 52 males) aged 20 to 50 with HIV-1 infection, who were undergoing ART in the Latvian Centre of Infectious Diseases. The median period of observation was 5.7 years. CD4+ T-cell count and viral load were analysed at the baseline and end of the period of obs…

0301 basic medicineClass (computer programming)MultidisciplinaryGeneral interestScienceQLatvianhiv-1Human leukocyte antigenhla class iiAntiretroviral therapylanguage.human_language03 medical and health sciences030104 developmental biology0302 clinical medicineImmunologyCohortlanguageAllelecd4+ t cells030217 neurology & neurosurgeryartProceedings of the Latvian Academy of Sciences. Section B, Natural Sciences
researchProduct